Your browser doesn't support javascript.
loading
Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best, Sarah A; Vandenberg, Cassandra J; Abad, Etna; Whitehead, Lachlan; Guiu, Laia; Ding, Sheryl; Brennan, Margs S; Strasser, Andreas; Herold, Marco J; Sutherland, Kate D; Janic, Ana.
Affiliation
  • Best SA; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
  • Vandenberg CJ; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia.
  • Abad E; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
  • Whitehead L; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia.
  • Guiu L; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003, Barcelona, Spain.
  • Ding S; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
  • Brennan MS; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia.
  • Strasser A; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003, Barcelona, Spain.
  • Herold MJ; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
  • Sutherland KD; Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia.
  • Janic A; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
Cell Death Dis ; 11(10): 877, 2020 10 20.
Article in En | MEDLINE | ID: mdl-33082333
ABSTRACT
TP53 is a critical tumor suppressor that is mutated in approximately 50% of human cancers. Unveiling the downstream target genes of TP53 that fulfill its tumor suppressor function is an area of intense investigation. Zmat3 (also known as Wig-1 or PAG608) is one such downstream target of p53, whose loss in hemopoietic stem cells lacking the apoptosis and cell cycle regulators, Puma and p21, respectively, promotes the development of leukemia. The function of Zmat3 in tumorigenesis however remains unclear. Here, to investigate which oncogenic drivers co-operate with Zmat3 loss to promote neoplastic transformation, we utilized Zmat3 knockout mice in models of c-MYC-driven lymphomagenesis and KrasG12D-driven lung adenocarcinoma development. Interestingly, unlike loss of p53, Zmat3 germline loss had little impact on the rate of tumor development or severity of malignant disease upon either the c-MYC or KrasG12D oncogenic activation. Furthermore, loss of Zmat3 failed to rescue KrasG12D primary lung tumor cells from oncogene-induced senescence. Taken together, we conclude that in the context of c-MYC-driven lymphomagenesis or mutant KrasG12D-driven lung adenocarcinoma development, additional co-occurring mutations are required to resolve Zmat3 tumor suppressive activity.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: RNA-Binding Proteins / DNA-Binding Proteins / Salivary alpha-Amylases / Carcinogenesis / Adenocarcinoma of Lung / Lung Neoplasms / Mutation Limits: Animals Language: En Journal: Cell Death Dis Year: 2020 Type: Article Affiliation country: Australia

Full text: 1 Database: MEDLINE Main subject: RNA-Binding Proteins / DNA-Binding Proteins / Salivary alpha-Amylases / Carcinogenesis / Adenocarcinoma of Lung / Lung Neoplasms / Mutation Limits: Animals Language: En Journal: Cell Death Dis Year: 2020 Type: Article Affiliation country: Australia